1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Stada And Xbrane Win EU Endorsement For Ranibizumab

Ximluci, Third Biosimilar Rival To Lucentis, Receives Positive Opinion From CHMP

 
• By Dave Wallace

Stada and Xbrane have celebrated an endorsement from the EMA’s CHMP for their Ximluci ranibizumab biosimilar rival to Lucentis. The development follows a setback for a parallel filing in the US.

EU flag reflected in eye
Stada and Xbrane are eyeing the third European biosimilar ranibizumab approval • Source: Shutterstock

Stada and Xbrane Biopharma have delivered on the promise of their proposed Lucentis (ranibizumab) biosimilar after their Ximluci version of the ophthalmology treatment received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending granting a pan-European marketing authorization.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.